News
Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
First Investigational Gene Therapy for Pitt Hopkins Syndrome Intended to Address Underlying Disease Biology
CTI Clinical Trial & Consulting Services (CTI), Mahzi Therapeutics Inc. (Mahzi), and the Pitt Hopkins Research Foundation (PHRF) are proud to announce a collaboration aimed at accelerating the development of a therapy for Pitt Hopkins Syndrome, a rare genetic neurodevelopmental disorder.
The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced that the Class of 2022 Henri Termeer Fellows has been named; the latest to receive this honor within the Fellowship program which began in 2018.